Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics to $34 from $32 and keeps a Buy rating on the shares. The firm said top-line revenue from sales of Korlym for Cushing’s disease and syndrome had 14% Y/Y growth, and an 11% increase sequentially. The company increased FY23 revenue guidance to $455M-$470M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics price target raised to $31 from $27 at Piper Sandler
- Corcept Therapeutics price target raised to $47.50 from $44 at Ladenburg
- Corcept Therapeutics price target raised to $32 from $30 at H.C. Wainwright
- Corcept Therapeutics reports Q2 EPS 25c, consensus 15c
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update